{
    "clinical_study": {
        "@rank": "114224", 
        "arm_group": {
            "arm_group_label": "Engager\u2122 aortic valve", 
            "arm_group_type": "Other", 
            "description": "Implantation of the Medtronic Engager\u2122 bioprosthesis via direct aortic approach"
        }, 
        "brief_summary": {
            "textblock": "To confirm the safety and performance of the Medtronic Engager\u2122 Transcatheter Aortic Valve\n      Implantation System via direct aortic approach in patients with symptomatic severe aortic\n      valve stenosis at high or extreme risk for surgical aortic valve replacement for which\n      treatment via direct aortic access is preferred."
        }, 
        "brief_title": "Engager Direct Aortic Clinical Study", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Severe aortic stenosis as defined by Doppler echocardiography: aortic valve area \u2264\n             0.8 cm2 (or AVA index \u2264 0.5 cm2/m2), or mean gradient \u2265 40 mmHg, or max velocity \u2265\n             4m/s\n\n          -  NYHA Functional Class II or greater;\n\n          -  Logistic EuroSCORE I \u2265 20%, or comorbidity judged by the heart team to pose an\n             absolute or relative contraindication for conventional aortic valve replacement;\n\n          -  Age \u2265 18 years;\n\n          -  The patient has been informed of the nature of the study and has consented to\n             participate, authorizing the collection and release of his/her medical information by\n             signing a consent form (\"Patient Informed Consent Form\"). Patient should understand\n             the implications of participating in the study and should be legally competent to\n             provide informed consent.\n\n        Exclusion Criteria:\n\n          -  Unicuspid or bicuspid aortic valve;\n\n          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation;\n\n          -  Left ventricular ejection fraction < 25%;\n\n          -  Left ventricular outflow obstruction, such as Hypertrophic Obstructive Cardiomyopathy\n             and severe septal hypertrophy;\n\n          -  Mitral or tricuspid regurgitation greater than 2+ by angiography or moderate by\n             echocardiography;\n\n          -  Patients with life expectancy less than 12 months due to an underlying non-cardiac\n             co-morbid disease;\n\n          -  Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine,\n             clopidogrel, Nitinol or contrast medium that cannot be adequately controlled with\n             pre-medication;\n\n          -  Sepsis or acute endocarditis;\n\n          -  Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding\n             diathesis, or coagulopathy;\n\n          -  Renal insufficiency assessed by creatinine clearance <  20 ml/min and/or end-stage\n             renal disease requiring chronic dialysis;\n\n          -  Active peptic ulcer or GI bleeding within 3 months from the planned index procedure;\n\n          -  Untreated clinically significant coronary artery disease requiring revascularization;\n\n          -  Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring\n             inotropic support or mechanical heart assistance;\n\n          -  Significant aortic disease, including abdominal and thoracic aortic aneurysm, defined\n             as maximal luminal diameter of 5 cm or greater;\n\n          -  Need for emergency surgery, cardiac or non-cardiac;\n\n          -  History of myocardial infarction in the last 6 weeks;\n\n          -  History of TIA or CVA in the last 6 months;\n\n          -  Therapeutic invasive cardiac procedure, with the exception of BAV, performed within\n             30 days of the planned date of valve implantation, or 6 months in the case of\n             drug-eluting stents;\n\n          -  Pre-existing prosthetic heart valve or prosthetic ring in any position;\n\n          -  Patient refuses a blood transfusion;\n\n          -  Patient is currently enrolled in another investigational device or drug trial that\n             may influence the outcome of this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789567", 
            "org_study_id": "RAE00807"
        }, 
        "intervention": {
            "arm_group_label": "Engager\u2122 aortic valve", 
            "description": "Implantation of the Medtronic Engager\u2122 bioprosthesis via direct aortic approach", 
            "intervention_name": "Engager\u2122 aortic valve", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 23, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20246"
                    }, 
                    "name": "Universit\u00e4res Herzzentrum Hamburg"
                }, 
                "investigator": {
                    "last_name": "Hendrik Treede, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04289"
                    }, 
                    "name": "Herzzentrum Leipzig"
                }, 
                "investigator": {
                    "last_name": "David Holzhey, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "80636"
                    }, 
                    "name": "Deutsches Herzzentrum M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Sabine Bleiziffer, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE1 7EH"
                    }, 
                    "name": "St. Thomas' Hospital"
                }, 
                "investigator": {
                    "last_name": "Vinayak Bapat, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW3 6NP"
                    }, 
                    "name": "Royal Brompton Hospital"
                }, 
                "investigator": {
                    "last_name": "Neil Moat, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Engager Direct Aortic Clinical Study: Medtronic Engager\u2122 Transcatheter Aortic Valve Implantation System Via Direct Aortic Approach", 
        "other_outcome": [
            {
                "measure": "Device success according to VARC2", 
                "safety_issue": "Yes", 
                "time_frame": "30 days post-procedure"
            }, 
            {
                "measure": "Composite 30-day safety endpoint according to VARC2", 
                "safety_issue": "Yes", 
                "time_frame": "30-days post-procedure"
            }, 
            {
                "measure": "Composite clinical efficacy endpoint after 30 days according to VARC2", 
                "safety_issue": "Yes", 
                "time_frame": "30-days post-procedure"
            }
        ], 
        "overall_contact": {
            "email": "kitty.schapira@medtronic.com", 
            "last_name": "Kitty Schapira, PhD", 
            "phone": "+31-43-356-6802"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Acute delivery system success, defined as bioprosthesis deployed in anatomically correct position and freedom from delivery system related complications at the end of the procedure.", 
            "safety_issue": "Yes", 
            "time_frame": "Within 30 days of implant procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789567"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medtronic Bakken Research Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Bakken Research Center", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}